Fierce Healthcare December 7, 2022
Teresa Carey

The healthcare industry is grappling with rising drug prices. The expectation is, though, that the wave of biosimilars launching next year will make a dent in healthcare costs. Paige Minemyer interviews Alan Lotvin, M.D., president of CVS Health’s Caremark pharmacy benefit manager, about biosimilars’ potential. 

...

Today's Sponsors

Transcarent
SalesSparx

Today's Sponsor

Health Edge

 
Topics: Biotechnology, Conferences / Podcast, Pharma / Biotech, Trends
J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries
Inflation Reduction Act Could Cut Medicare Drug Spending by 5%, Study Suggests
Pfizer and Ada Health Inc. To Launch Nationwide Online COVID-19 Care Journey
Chutes & Ladders—Ginkgo BioWorks CEO to lead federal biotech commission
Smoothing Medicare Part D Out-Of-Pocket Costs Under The Inflation Reduction Act

Share This Article